Medical device company ResMed (NYSE:RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 10.8% year on year to $1.43 bi...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Medical device company ResMed (NYSE:RMD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 10.8% year on year to $1.43 billion...
Medical device company ResMed (NYSE:RMD) will be announcing earnings results this Thursday afternoon. Here’s what to look for. ResMed beat analysts’ revenue ...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
ResMed Inc. offers a sustainable dividend with a 10-year growth history, backed by strong profitability, a low payout ratio, and a rock-solid balance sheet for durable passive income.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
What Happened? Shares of medical device company ResMed (NYSE:RMD) fell 2.6% in the afternoon session after its Chairman and CEO, Michael J. Farrell, sold sha...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se...
Over the past six months, ResMed’s shares (currently trading at $252.56) have posted a disappointing 11.7% loss, well below the S&P 500’s 5.9% gain. This might have investors contemplating their next move.
